888 related articles for article (PubMed ID: 17492053)
1. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.
Sanada S; Hakuno D; Higgins LJ; Schreiter ER; McKenzie AN; Lee RT
J Clin Invest; 2007 Jun; 117(6):1538-49. PubMed ID: 17492053
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling.
Seki K; Sanada S; Kudinova AY; Steinhauser ML; Handa V; Gannon J; Lee RT
Circ Heart Fail; 2009 Nov; 2(6):684-91. PubMed ID: 19919994
[TBL] [Abstract][Full Text] [Related]
3. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature.
Demyanets S; Kaun C; Pentz R; Krychtiuk KA; Rauscher S; Pfaffenberger S; Zuckermann A; Aliabadi A; Gröger M; Maurer G; Huber K; Wojta J
J Mol Cell Cardiol; 2013 Jul; 60():16-26. PubMed ID: 23567618
[TBL] [Abstract][Full Text] [Related]
4. The biology of ST2: the International ST2 Consensus Panel.
Pascual-Figal DA; Januzzi JL
Am J Cardiol; 2015 Apr; 115(7 Suppl):3B-7B. PubMed ID: 25665766
[TBL] [Abstract][Full Text] [Related]
5. Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress.
Veeraveedu PT; Sanada S; Okuda K; Fu HY; Matsuzaki T; Araki R; Yamato M; Yasuda K; Sakata Y; Yoshimoto T; Minamino T
Biochem Pharmacol; 2017 Aug; 138():73-80. PubMed ID: 28450225
[TBL] [Abstract][Full Text] [Related]
6. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression.
Sweet MJ; Leung BP; Kang D; Sogaard M; Schulz K; Trajkovic V; Campbell CC; Xu D; Liew FY
J Immunol; 2001 Jun; 166(11):6633-9. PubMed ID: 11359817
[TBL] [Abstract][Full Text] [Related]
7. Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling.
Ho JE; Chen WY; Chen MH; Larson MG; McCabe EL; Cheng S; Ghorbani A; Coglianese E; Emilsson V; Johnson AD; Walter S; Franceschini N; O'Donnell CJ; ; ; Dehghan A; Lu C; Levy D; Newton-Cheh C; ; Lin H; Felix JF; Schreiter ER; Vasan RS; Januzzi JL; Lee RT; Wang TJ
J Clin Invest; 2013 Oct; 123(10):4208-18. PubMed ID: 23999434
[TBL] [Abstract][Full Text] [Related]
8. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation.
Hayakawa H; Hayakawa M; Kume A; Tominaga S
J Biol Chem; 2007 Sep; 282(36):26369-80. PubMed ID: 17623648
[TBL] [Abstract][Full Text] [Related]
9. HIMF (Hypoxia-Induced Mitogenic Factor)-IL (Interleukin)-6 Signaling Mediates Cardiomyocyte-Fibroblast Crosstalk to Promote Cardiac Hypertrophy and Fibrosis.
Kumar S; Wang G; Zheng N; Cheng W; Ouyang K; Lin H; Liao Y; Liu J
Hypertension; 2019 May; 73(5):1058-1070. PubMed ID: 30827145
[TBL] [Abstract][Full Text] [Related]
10. A role for soluble ST2 in vascular remodeling associated with obesity in rats.
Martínez-Martínez E; Miana M; Jurado-López R; Rousseau E; Rossignol P; Zannad F; Cachofeiro V; López-Andrés N
PLoS One; 2013; 8(11):e79176. PubMed ID: 24265755
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor-2 mediates adaptive cardiac hypertrophy in response to pressure overload through interleukin-1β upregulation via nuclear factor κB activation.
Higashikuni Y; Tanaka K; Kato M; Nureki O; Hirata Y; Nagai R; Komuro I; Sata M
J Am Heart Assoc; 2013 Nov; 2(6):e000267. PubMed ID: 24249711
[TBL] [Abstract][Full Text] [Related]
12. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load.
Bartunek J; Delrue L; Van Durme F; Muller O; Casselman F; De Wiest B; Croes R; Verstreken S; Goethals M; de Raedt H; Sarma J; Joseph L; Vanderheyden M; Weinberg EO
J Am Coll Cardiol; 2008 Dec; 52(25):2166-74. PubMed ID: 19095135
[TBL] [Abstract][Full Text] [Related]
13. The role of the Interleukin 1 receptor-like 1 (ST2) and Interleukin-33 pathway in cardiovascular disease and cardiovascular risk assessment.
Willems S; Hoefer I; Pasterkamp G
Minerva Med; 2012 Dec; 103(6):513-24. PubMed ID: 23229370
[TBL] [Abstract][Full Text] [Related]
14. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans.
Pusceddu I; Dieplinger B; Mueller T
Clin Chim Acta; 2019 Aug; 495():493-500. PubMed ID: 31136737
[TBL] [Abstract][Full Text] [Related]
15. ST2/IL-33 signaling in cardiac fibrosis.
Vianello E; Dozio E; Tacchini L; Frati L; Corsi Romanelli MM
Int J Biochem Cell Biol; 2019 Nov; 116():105619. PubMed ID: 31561019
[TBL] [Abstract][Full Text] [Related]
16. Characterization of signaling pathways activated by the interleukin 1 (IL-1) receptor homologue T1/ST2. A role for Jun N-terminal kinase in IL-4 induction.
Brint EK; Fitzgerald KA; Smith P; Coyle AJ; Gutierrez-Ramos JC; Fallon PG; O'Neill LA
J Biol Chem; 2002 Dec; 277(51):49205-11. PubMed ID: 12368275
[TBL] [Abstract][Full Text] [Related]
17. Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33.
Chen WY; Hong J; Gannon J; Kakkar R; Lee RT
Proc Natl Acad Sci U S A; 2015 Jun; 112(23):7249-54. PubMed ID: 25941360
[TBL] [Abstract][Full Text] [Related]
18. Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction.
Asensio-Lopez MC; Lax A; Fernandez Del Palacio MJ; Sassi Y; Hajjar RJ; Januzzi JL; Bayes-Genis A; Pascual-Figal DA
J Mol Cell Cardiol; 2019 May; 130():216-233. PubMed ID: 30998979
[TBL] [Abstract][Full Text] [Related]
19. [The physiologic and pathophysiologic role of stimulating growth factor ST2.].
Dyleva YA; Gruzdeva OV; Akbasheva OE; Uchasova EG; Barbarash OL
Klin Lab Diagn; 2017; 62(10):599-605. PubMed ID: 30821940
[TBL] [Abstract][Full Text] [Related]
20. The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease.
Miller AM; Liew FY
Pharmacol Ther; 2011 Aug; 131(2):179-86. PubMed ID: 21356240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
